Jeffrey P. Bodle counsels emerging businesses and other innovative high-growth companies at every stage of their business lifecycle—including in mergers and acquisitions (M&A), angel and venture capital financings, IPOs, securities offerings and compliance, corporate partnering, joint ventures, formation advice, and other strategic and outside general counsel matters. Jeff also represents seed, venture capital, private equity, institutional, and strategic investors in financing, M&A, and portfolio company transactions. Jeff focuses primarily in the technology, healthcare, life sciences, venture capital, and private equity fields.
Jeff nurtures entrepreneurs and early-stage clients by reviewing their business plans, helping identify appropriate financing sources, and connecting them to various emerging business and venture capital communities.
He also provides legal and strategic advice on choice of entity and formation issues, equity and incentive structures, equity and debt financing structures, and the execution of growth strategies, including M&A. He counsels boards of directors and senior management on corporate governance, securities compliance, and IP matters, as well as offering advice on exit strategies, including preparing for and executing a sale transaction or IPO, or transitioning from a private to a public company.
Jeff participates in the firm’s “Connect at Morgan Lewis” program, which brings together investors and entrepreneurs and helps clients refine their investor presentations through individual coaching sessions. An active member of the Greater Philadelphia and Pennsylvania startup, emerging business, and venture capital communities, including the IT Investment Advisory Committee for the Ben Franklin Technology Partners of Southeastern Pennsylvania, he speaks regularly on startup, emerging business, and venture capital topics and serves as a coach and judge at investor and venture fairs and business plan competitions.
Representation of technology, healthcare, life sciences and clean technology companies and venture capital investors in dozens of venture capital financings involving an aggregate of more than $1 billion in proceeds raised.
Representation of a strategic venture capital fund affiliated with one of the world’s leading cable and communications companies in multiple strategic venture capital investments.
Representation of a NASDAQ-listed cancer diagnostic medical device company in its initial public offering, follow-on financings, and pre-IPO venture capital financings.
Representation of multiple technology and life sciences companies in sales to publicly traded and other strategic buyers.
Representation of an international media company with an education focus in connection with several strategic venture investments in innovative education companies.
Representation of a multinational specialty pharmaceutical company in a Rule 144A offering of $400 million in senior unsecured notes.
Representation of an AMEX-listed medical injection device company in multiple PIPE financings.
Representation of a pension fund sponsored by a Fortune 100 company in multiple private equity investments.